Adoptive cell transfer (ACT) therapies for cancer patients have failed to fulfill their therapeutic promise, due to the transfer of short-lived and terminally differentiated cells. A lack of means for developing durable T cell potency has hampered ACT advancement in the clinic. Understanding and manipulating the pathways that sustain T cell memory will potentially unlock durable responses to tumors. We recent found that IL-17A/IFN- ?/IL-22-producing CD4+ T cells that express enzymatically active CD26 on their cell surface?termed human CD26hiCD4+ T cells?demonstrate exquisite responses to tumors compared to Th1, Th2 or Th17 cells. Further investigation revealed that these cells potently induce the expansion and engraftment of cytotoxic CD8+ T cells in vivo. Interestingly, we found that abrogating the enzymatic activity of CD26 on CD26hiCD4+ but not on CD8+ or CD26negCD4+ T cells with Alogliptin impaired their capacity to secrete IFN-?. Collectively, our data suggest that CD26 plays a role in the cytotoxicity of CD26hiCD4+ T cells and could augment CD8+ T cell engraftment in vivo, in turn mediated curative responses in mice with murine and human tumors. The importance of CD26 on CD26hiCD4+ T cell function, metabolism and cytotoxicity will be investigated using various tools to pharmaceutically or genetically manipulate CD26 enzyme activity. Based on our new findings, the loss of function, metabolism and memory induced by the inhibition of CD26 enzymatic activity could potentially reduce the ability of CD26hiCD4+ T cells to support CD8+ T cells. It is important to deduce how CD26 on CD26hiCD4+ T cells cancer immunotherapy and if this activity and co-signaling molecules can be targeted for enhance therapy against this aggressive pancreatic cancer. We propose to gain further insight into CD26hiCD4+ T cell-mediated tumor immunity, hypothesizing that CD26 plays a crucial role in the anti-tumor activity of human CD26hiCD4+ T cells as well as their ability to support CD8+ T cells (Aim 1), and that these cells have unique self-renewing properties that prolong their efficacy of cancer immunotherapy after multiple rounds of serial transfer (Aim 2). We will also target co-stimulatory molecules on these cells to enhance their capacity to kill human pancreatic cancer (Aim 3). Our proposed research is expected to demonstrate that manipulation of the CD26 pathway may induce durable immunity against the growth and recurrence of advanced malignancies.

Public Health Relevance

We seek to understand how the nature of CD26 on augmenting memory antitumor CD26hiCD4+ T cells, which hold promise in the context of cancer immunotherapy for mounting prolonged, robust responses against human malignancies. Our studies of enzymatic CD26 on human T cell antitumor function and memory phenotype will allow us to harness/target those pathways to generate more potent, persistent T cells and elicit prolonged positive patient immune responses against cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA208514-05
Application #
10227546
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Mccarthy, Susan A
Project Start
2016-07-01
Project End
2021-06-30
Budget Start
2020-08-17
Budget End
2021-06-30
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Emory University
Department
Surgery
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Johnson, C Bryce; May, Bennett R; Riesenberg, Brian P et al. (2018) Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. Cancer Res 78:3067-3074
Knochelmann, Hannah M; Dwyer, Connor J; Bailey, Stefanie R et al. (2018) When worlds collide: Th17 and Treg cells in cancer and autoimmunity. Cell Mol Immunol 15:458-469
Knochelmann, Hannah M; Smith, Aubrey S; Dwyer, Connor J et al. (2018) CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. Front Immunol 9:1740
Malik, Brian T; Byrne, Katelyn T; Vella, Jennifer L et al. (2017) Resident memory T cells in the skin mediate durable immunity to melanoma. Sci Immunol 2:
Bowers, Jacob S; Nelson, Michelle H; Majchrzak, Kinga et al. (2017) Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion. JCI Insight 2:e90772
Bailey, Stefanie R; Nelson, Michelle H; Majchrzak, Kinga et al. (2017) Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. Nat Commun 8:1961
Neal, Lillian R; Bailey, Stefanie R; Wyatt, Megan M et al. (2017) The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies. J Immunol Res Ther 2:68-79
Bowers, Jacob S; Majchrzak, Kinga; Nelson, Michelle H et al. (2017) PI3K? Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells. Front Immunol 8:1221
Rachidi, Saleh; Metelli, Alessandra; Riesenberg, Brian et al. (2017) Platelets subvert T cell immunity against cancer via GARP-TGF? axis. Sci Immunol 2:
Chan, Sherine S L (2017) Inherited mitochondrial genomic instability and chemical exposures. Toxicology 391:75-83